Patent · US Expired

Process for treating tumors with cytotoxic substances

US6582690B1 · kind B1 · utility

0Cited by

3References

5Claims

0Family size

Assignee

Max Delbrück-Centrum Für Molekulare Medizin · DE

Inventors

Ulrike Stein · Schwanebeck, DE
Wolfgang Walther · Berlin, DE
Peter Schlag · Berlin, DE

Key dates

Filing date	Mar 19, 1999
Grant date	Jun 24, 2003
Priority date	—
Expiry date	Mar 19, 2019

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention concerns a cytotoxic, MDR-associated substance for producing a therapeutic agent for tumor therapy, which is characterized by a) the tumor cells of a tumor patient are chemosensitized with a cytokine, b) the scope of expression of one or more MDR-associate genes (e.g. mdrl, Mrp, Lrp) in the tumor tissues of the patient is determined according to the beginning of the cytokine treatment, c) the time domain is determined, in which the expression of one or more MDR-associate genes is substantially reduced by the cytokine treatment, d) the patient is treated in the determined time domain (“therapeutic window”) with a therapeutically effective amount of a cytotoxic, MDR-associated substance, the effectiveness of which is influenced (enhanced) by the expression of one or more MDR-associate genes. The use of said substance leads to an improved tumor therapy.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.